Current Liabilities
Other Commercial Liabilities
Boston Scientific Other Commercial Liabilities decreased by 21.5% to $2.51B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 6.8%, from $2.35B to $2.51B. Over 5 years (FY 2020 to FY 2025), Other Commercial Liabilities shows an upward trend with a 7.8% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Liabilities
First reportedQ4 2014
Last reportedQ1 2026May 1, 2026
Metric ID:
commercial_liabilities_otherHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.44B | $2.42B | $2.44B | $2.31B | $2.20B | $1.97B | $2.16B | $1.92B | $2.16B | $2.26B | $2.65B | $2.08B | $2.32B | $2.46B | $2.77B | $2.35B | $2.80B | $2.98B | $3.20B | $2.51B |
| QoQ Change | — | -1.0% | +0.7% | -5.3% | -4.7% | -10.2% | +9.4% | -11.2% | +12.8% | +4.2% | +17.3% | -21.3% | +11.4% | +6.0% | +12.7% | -15.1% | +18.8% | +6.6% | +7.4% | -21.5% |
| YoY Change | — | — | — | — | -10.0% | -18.4% | -11.3% | -16.8% | -1.5% | +14.2% | +22.5% | +8.6% | +7.2% | +9.1% | +4.8% | +13.0% | +20.6% | +21.2% | +15.4% | +6.8% |
Range$1.92B – $3.20B
CAGR+0.6%
Avg YoY Growth+5.3%
Median YoY Growth+7.9%
Other Commercial Liabilities at Other Companies
Frequently Asked Questions
- What is Boston Scientific's other commercial liabilities?
- Boston Scientific (BSX) reported other commercial liabilities of $2.51B in Q1 2026.
- How has Boston Scientific's other commercial liabilities changed year-over-year?
- Boston Scientific's other commercial liabilities increased by 6.8% year-over-year, from $2.35B to $2.51B.
- What is the long-term trend for Boston Scientific's other commercial liabilities?
- Over 5 years (2020 to 2025), Boston Scientific's other commercial liabilities has grown at a 7.8% compound annual growth rate (CAGR), from $2.20B to $3.20B.